Insmed Strikes $500M Deal with Leerink for Growth and R&D

Insmed (INSM) has released an update.

Insmed Incorporated has entered into a new agreement with Leerink Partners to potentially sell up to $500 million of its common stock. This flexible arrangement allows Insmed to support its commercial and development activities for its drug ARIKAYCE, research on brensocatib, and other corporate endeavors. The agreement replaces a previous $250 million agreement and will enable sales through various market transactions, with Leerink earning a 3% commission on sales. The partnership is designed to bolster Insmed’s financial positioning without any obligation to sell.

For further insights into INSM stock, check out TipRanks’ Stock Analysis page.